SCRIB and breast cancer: However, CRISPR and RNAi knockdown revealed no recurrent dependencies characterizing these cell lines with SCRIB, VANGL2 and NOS1AP amplifications that could suggest therapeutic avenues in breast cancers with these amplifications.